WASHINGTON, D.C. — Leaders of the House Oversight Committee want EpiPen maker Mylan to explain why company CEO Heather Bresch failed to tell Congress that profit rates the company claimed for its EpiPen were calculated after taxes.
Bresch, the daughter of U.S. Sen. Joe Manchin, repeatedly told the panel last month that Mylan made just $50 in profit for EpiPens sold for more than $300 apiece.
Lawmakers said in a letter released Monday Bresch’s calculations were made after factoring in the 37.5 percent U.S. tax rate. Before taxes, the EpiPen profit is $160 for a two-pack.
Committee Chairman Jason Chaffetz (R-Utah) and Rep. Elijah Cummings (D-Md.), said Bresch’s failure to disclose the tax assumptions raised questions about her honesty at a hearing held Sept. 21.